Adam D. Cohen, MD

Adam D. Cohen, MD, discusses the mechanism of action of cevostamab in relapsed/refractory multiple myeloma.

Adam D. Cohen, MD, discusses future research directions for cevostamab in relapsed/refractory multiple myeloma.

Adam D. Cohen, MD, discusses phase 1 efficacy data for cevostamab in relapsed/refractory multiple myeloma.

Adam D. Cohen, MD, discusses the potential role of FcRH5 as a target and the ongoing investigation of cevostamab in multiple myeloma.

Adam D. Cohen, MD, discusses unmet needs and areas for future investigation within the relapsed/refractory multiple myeloma treatment landscape.

Adam D. Cohen, MD, discusses the current landscape of treatment options in multiple myeloma, and elaborates on attempts to utilize these options in earlier lines of therapy.

Adam D. Cohen, MD, discusses the efficacy of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma.

Adam D. Cohen, MD, discusses the safety profile of ciltacabtagene autoleucel in patients with multiple myeloma, based on data from the phase 2 CARTITUDE-2 study.

Adam D. Cohen, MD, discusses outcomes with ciltacabtagene autoleucel, as demonstrated in the phase 2 CARTITUDE-2 study in patients with multiple myeloma.

Adam D. Cohen, MD, discusses mitigation strategies that can be used for patients with relapsed/refractory multiple myeloma who are receiving the CAR T-cell therapy ciltacabtagene autoleucel.

Adam D. Cohen, MD, discusses the ongoing phase II DREAMM-2 study in multiple myeloma.